Stealth receives FDA orphan drug designation for elamipretide to treat DMD

By vbandhakavi

Stealth BioTherapeutics has received Orphan Drug Designation from the US Food and Drug Administration (FDA) Office of Orphan Products Development for elamipretide to treat Duchenne muscular dystrophy (DMD) patients.